Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine vs Fludrocortisone in Vasovagal Syncope (COMFORTS)
NCT04595942Phase 3Unknown
- Sponsor
- Tehran Heart Center
- Start
- Nov 2020
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of midodrine and fludrocortisone in vasovagal syncope (3 arms), sponsored by Tehran Heart Center. Primary endpoint: Time to first episode of syncope at 12 months. Status: unknown.
02
Drugs
midodrinefludrocortisone
03
Conditions
vasovagal syncope
Beyond the preview
Go deeper on NCT04595942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04595942.